December 09, 2021
Article
Fam-trastuzumab deruxtecan-nxki led to prolonged progression-free survival and higher responses compared with ado-trastuzumab emtansine as second-line therapy in patients with HER2-positive metastatic breast cancer.
December 08, 2021
Article
Data presented at the San Antonio Breast Cancer Sympsium found that in patients with a low HER2 immunohistochemistry (IHC) score of 0 or 1+, poor agreement in the evaluation of these patients exist using standard HER2 assays.
December 07, 2021
Article
Updated results from the phase 3 3KEYNOTE-355 trial indicate a new standard of care for patients with metastatic triple-negative breast cancer in patients with a PD-L1 combined positive score of 10 or higher.
October 21, 2021
Article
Small cell lung cancer is the most aggressive form of lung cancer and mostly occurs in smokers. Although the disease has proved to be sensitive to chemotherapy and radiation, responses are short and those who relapse have short survival.
September 21, 2021
Article
In patients with extensive-stage small cell lung cancer, durvalumab added to platinum/etoposide chemotherapy continued to demonstrate an overall survival improvement compared with chemotherapy alone with a favorable safety profile, according to updated data from the phase 3 CASPIAN trial.
September 21, 2021
Article
In patients with estrogen receptor–positive, HER2-negative early breast cancer, giredestrant resulted in a greater relative reduction in Ki67 score from baseline to week 2 of a window of opportunity phase vs anastrozole.